Speciality Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Education Dialogues
    • Business Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Speciality Medical Dialogues
    • Editorial
    • News
        • Anesthesiology
        • Cancer
        • Cardiac Sciences
        • Critical Care
        • Dentistry
        • Dermatology
        • Diabetes and Endo
        • Diagnostics
        • ENT
        • Featured Research
        • Gastroenterology
        • Geriatrics
        • Medicine
        • Nephrology
        • Neurosciences
        • Nursing
        • Obs and Gynae
        • Ophthalmology
        • Orthopaedics
        • Paediatrics
        • Parmedics
        • Pharmacy
        • Psychiatry
        • Pulmonology
        • Radiology
        • Surgery
        • Urology
    • Practice Guidelines
        • Anesthesiology Guidelines
        • Cancer Guidelines
        • Cardiac Sciences Guidelines
        • Critical Care Guidelines
        • Dentistry Guidelines
        • Dermatology Guidelines
        • Diabetes and Endo Guidelines
        • Diagnostics Guidelines
        • ENT Guidelines
        • Featured Practice Guidelines
        • Gastroenterology Guidelines
        • Geriatrics Guidelines
        • Medicine Guidelines
        • Nephrology Guidelines
        • Neurosciences Guidelines
        • Obs and Gynae Guidelines
        • Ophthalmology Guidelines
        • Orthopaedics Guidelines
        • Paediatrics Guidelines
        • Psychiatry Guidelines
        • Pulmonology Guidelines
        • Radiology Guidelines
        • Surgery Guidelines
        • Urology Guidelines
    LoginRegister
    Speciality Medical Dialogues
    LoginRegister
    • Home
    • Editorial
    • News
      • Anesthesiology
      • Cancer
      • Cardiac Sciences
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endo
      • Diagnostics
      • ENT
      • Featured Research
      • Gastroenterology
      • Geriatrics
      • Medicine
      • Nephrology
      • Neurosciences
      • Nursing
      • Obs and Gynae
      • Ophthalmology
      • Orthopaedics
      • Paediatrics
      • Parmedics
      • Pharmacy
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
    • Practice Guidelines
      • Anesthesiology Guidelines
      • Cancer Guidelines
      • Cardiac Sciences Guidelines
      • Critical Care Guidelines
      • Dentistry Guidelines
      • Dermatology Guidelines
      • Diabetes and Endo Guidelines
      • Diagnostics Guidelines
      • ENT Guidelines
      • Featured Practice Guidelines
      • Gastroenterology Guidelines
      • Geriatrics Guidelines
      • Medicine Guidelines
      • Nephrology Guidelines
      • Neurosciences Guidelines
      • Obs and Gynae Guidelines
      • Ophthalmology Guidelines
      • Orthopaedics Guidelines
      • Paediatrics Guidelines
      • Psychiatry Guidelines
      • Pulmonology Guidelines
      • Radiology Guidelines
      • Surgery Guidelines
      • Urology Guidelines
    • Home
    • News
    • Diabetes and Endo
    • Insulin degludec safe...

    Insulin degludec safe ,effective in children with T1 Diabetes

    Written by Vinay Singh singh Published On 2018-10-19T19:15:16+05:30  |  Updated On 19 Oct 2018 7:15 PM IST
    Insulin degludec safe ,effective in children with T1 Diabetes

    Researchers at Indraprastha Apollo Hospital, New Delhi, have found that Insulin degludec is safe and effective in children with T1 Diabetes


    The new study published in the International Journal of Pediatric Endocrinology reports that Insulin Degludec (IDeg) treatment in Indian children and adolescents with Type1 Diabetes Mellitus results in significant glycemic control with reduced hypoglycemic episodes and bolus insulin doses over the period of 26 weeks.


    The researchers evaluated 30 pediatric and adolescent patients with T1DM who received IDeg (once daily) along with rapid-acting mealtime insulin for 26 weeks. All patients were assessed for anthropometric data, duration of diabetes, glycated hemoglobin (HbA1c), insulin requirement and the number of hypoglycemic episodes at pre- and post-baseline, along with the daily self-monitoring of blood glucose.


    Read Also: Early signs of Diabetes detectable 20 years before diagnosis



    The key study findings include:




    • There was a significant decline in HbA1c, FPG and bolus insulin dose from baseline to 26 weeks in the overall population (HbA1c: 9.65 to 8.60; FPG: 156.93 ± 42.373 to 109.37 mg/dL; bolus insulin dose: 0.49 ± U/kg/day to 0.35 U/kg/day).

    • The basal insulin dose was significantly higher at 26 weeks compared to baseline dose (0.42 U/kg/day to 0.46 U/kg/day).

    • There was no significant change in BMI at 26 weeks.

    • None of the patients experienced any DKA episode for 26 weeks.

    • 7% of patients had experienced at least one symptomatic hypoglycemia episode.

    • On CGMS among the patients who were shifted from Glargine to degludec hypoglycemia were reduced significantly (overall hypoglycemia: 1.92 to 0.35 episodes over 3 days while nocturnal hypoglycemia: 0.92 to 0.21 episodes).

    • None of the patients had a severe hypoglycemic episode.


    “The International Society for Pediatrics and Adolescent Diabetes, recommended target glycaemic level as HbA1c, <7.5% in children and adolescents with T1DM, regardless of age. IDeg as a basal insulin, in basal-bolus regimens, helps in achieving optimal glycemic controls with minimal or no episodes of hypoglycemia, ”write the authors.


    Read Also: Managing type 1 diabetes in adolescents and kids:New position statement by ADA
    “Our results were in parallel to the previously reported literature. However, further long-term prospective studies are required to evaluate the long-term effects,” they added.


    The study concluded that IDeg is found to be safe and effective long-acting basal insulin that can be used in Indian pediatric population with T1DM.


    Type 1 diabetes mellitus (T1DM), is one of the most common pediatric endocrine illnesses. Across the world, around 78,000 children under 15 years of age are estimated to develop T1DM annually. Recent reports have estimated that 24% and 23% of pediatric diabetic patients belong to European and South-East Asian regions, respectively whereas in India alone there are about 97,700 children with T1DM.


    For reference log on to https://doi.org/10.1186/s13633-018-0059-0


    boluschildrencontroldabetes mellitusDegludecDelhidiabetesepisodesglycemichypoglycemicindianIndraprastha Apollo HospitalinsulinInternational Journal of Pediatric Endocrinologyreduced
    Source : With inputs from International Journal of Pediatric Endocrinology

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Vinay Singh singh
    Vinay Singh singh
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 12 Oct 2022 7:06 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok